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Abstract
Frontotemporal lobar degeneration (FTLD) is pathologically subdivided based on the presence of particular
pathological proteins that are identified in inclusion bodies observed post-mortem. The FTLD-FUS subgroup is defined
by the presence of the fused in sarcoma protein (FUS) in pathological inclusions. FUS is a heterogeneous nuclear
ribonucleoprotein (hnRNP) protein and a member of the FET (FUS, EWS, TAF15) protein family. It shuttles between the
nucleus and cytoplasm, and has been implicated in many cellular functions including translation, splicing, and RNA
transport. EWS, TAF15 and the nuclear import receptor transportin have been shown to co-accumulate with FUS in
neuronal inclusions specifically in FTLD-FUS, with transportin-positive inclusions most frequently observed. Here, we
report the identification of hnRNP R and hnRNP Q in neuronal cytoplasmic and intranuclear inclusions in the frontal
cortex and hippocampus of FTLD-FUS patients, as frequently as transportin. hnRNP R and hnRNP Q were not found in
the characteristic pathological inclusions observed in FTLD-TDP (subtypes A-C). Additionally, we studied the expression
of hnRNP R in the frontal and temporal cortices from patients with FTLD and found significantly increased expression
of the heterogeneous nuclear ribonucleoprotein R in several FTLD disease groups. Our identification of the frequent
presence of hnRNP R and hnRNP Q in FTLD-FUS inclusions suggests a potential role for these hnRNPs in FTLD-FUS
pathogenesis and supports the role of dysfunctional RNA metabolism in FTLD.
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Introduction
Frontotemporal lobar degeneration (FTLD) is a broad
term used to describe the major pathology underlying a
clinically heterogeneous group of neurodegenerative dis-
eases characterised by progressive changes in executive
function, behaviour and/or language. Macroscopically,
FTLD is typically identified by significant atrophy of the
frontal and temporal cortices of the brain, while micro-
scopically, the disease is characterised by the presence of
abnormal intracellular protein aggregates. FTLD can be
pathologically sub-divided into three major groups based
on the main protein species identified in pathological in-
clusions; tau (FTLD-Tau), the TAR DNA-binding protein
43 (TDP-43) (FTLD-TDP) or the fused in sarcoma
(FUS) protein (FTLD-FUS) [28, 35, 36]. Each group can
be further sub-categorised based on the types of inclu-
sions present. The FTLD-FUS group encompasses three
pathological diagnoses; neurofilament inclusion body
disease (NIFID), basophilic inclusion body disease
(BIBD) and atypical frontotemporal lobar degeneration
with ubiquitinated inclusions (aFTLD-U), collectively ac-
counting for approximately 5–10% of all FTLD cases
[27, 33, 39, 41, 42, 55]. A commonality among all three
is the presence of pathological inclusions containing the
FUS protein.
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FUS is a multi-functional 53 kDa DNA/RNA-binding
protein, belonging to the FET protein family. These are
highly conserved, nuclear proteins that are ubiquitously
expressed and are involved in various aspects of DNA and
RNA metabolism, including RNA processing, transcrip-
tion, splicing, transport and DNA repair [2, 26, 29, 54].
FET proteins are able to shuttle continuously between the
nucleus and cytoplasm via the interaction between their
non-classical nuclear localisation signal, PY-NLS, and the
nuclear import protein, transportin 1 (TRN1) [24, 58, 59],
which has been shown to label all FUS positive inclusions
[6]. In addition to FUS, the two other members of the
FET protein family, Ewing’s sarcoma (EWS) and
TATA-binding protein-associated factor 15 (TAF15), have
also been found to label a proportion of pathological in-
clusions in FTLD-FUS [40]. This observation has led to
the hypothesis that disruption of the nuclear import of
FET proteins by TRN1 may be contributing to pathogen-
esis in FTLD-FUS [43].
However, it is not only FET proteins that have been
identified as components of pathological inclusions in
FTLD-FUS cases. Our group previously reported several
other RNA binding proteins are present to varying de-
grees within these inclusions following pathological and
biochemical analysis of the heterogeneous nuclear ribo-
nucleoprotein (hnRNP) family of proteins in FTLD-FUS
cases [17]. Prompted by the fact that, in addition to be-
ing a FET protein, FUS can also be classified as an
hnRNP (hnRNP P2) [7], a screen of 11 hnRNPs indi-
cated the infrequent presence of hnRNP D, G, I and L
and the more frequent presence of the TRN1 cargo,
hnRNP A1, in FUS-positive neuronal cytoplasmic and
intranuclear inclusions [17].
hnRNPs are a large family of proteins, which can shut-
tle between the nucleus and cytoplasm to carry out a
variety of functions linked to nucleic acid metabolism,
including nuclear (transcription, splicing, 5′ capping and
polyadenylation) and cytoplasmic (mRNA transport, sta-
bility, translation and degradation) functions [15, 20].
The different hnRNPs frequently have overlapping func-
tions and often perform their functions as part of a lar-
ger co-operative protein complex, however they also
have individual specialised roles that are dependent on
specific RNA-protein or protein-protein interactions
[15, 20]. Given that hnRNPs perform a diverse range of
functions linked to RNA metabolism, the presence of
various hnRNPs in FUS inclusions implies that the
pathogenesis of FTLD-FUS extends beyond FET pro-
teins, TRN1 cargoes and dysfunctional nuclear import,
and implicates a wider dysregulation of RNA binding
protein metabolism. Here we provide further evidence to
support this hypothesis by reporting the presence of two
additional hnRNP proteins – hnRNP R and hnRNP
Q - in pathological inclusions specifically in FTLD-FUS.
We used immunohistochemical, biochemical and ex-
pression analysis to investigate a role for hnRNP R in
FTLD. Due to the sequence homology between hnRNP
R and hnRNP Q we investigated the presence of both
proteins in the pathological inclusions of FTLD-FUS and
undertook a semi-quantitative assessment of patho-
logical inclusions containing both hnRNP R and hnRNP
Q compared to inclusions containing FUS and/or TRN1.
We found hnRNP R and hnRNP Q to be present in es-




Brains were donated to the Queen Square Brain Bank
for Neurological Disorders (UCL Queen Square Institute
of Neurology) and the Medical Research Council
London Brain Bank for Neurodegenerative Diseases
(Institute of Psychiatry, King’s College, London). The
demographic and clinical data of all cases used in this
study are listed in Table 1. FTLD-FUS cases used in this
study had previously been pathologically diagnosed as
NIFID (n = 6, cases 1–6) or aFTLD-U (n = 7, cases 7–13)
and have been previously reported [27]. FTLD-TDP
cases used included FTLD-TDP A (n = 19), FTLD-TDP
B (n = 3), FTLD-TDP C (n = 7) and neurologically nor-
mal controls (n = 6). Ethical approval for the study was
obtained from the Local Research Ethics Committee of
the National Hospital for Neurology and Neurosurgery.
mRNA expression analysis
Total RNA was extracted from the frontal and
temporal cortices of FTLD-FUS (n = 5), FTLD-TDP A
(n = 19), FTLD-TDP B (n = 3), FTLD-TDP C (n = 7)
and normal controls (n = 6) using the Qiagen RNeasy
kit. 100 ng of total RNA from each sample was ana-
lysed using the NanoString nCounter analysis system
(Nanostring Technologies, Seattle, WA) using a pre-
designed codeset, which has been previously reported
[17]. The codeset contained probes for detection of
the gene of interest; HNRNPR. Probes were designed
according to the manufacturer’s design principles [18].
The laboratory running the assay was blinded to case
diagnoses, and samples of cases or controls were ran-
domly assigned to plates to avoid run-order bias. Raw
counts were subjected to a technical normalization
and normalized to the geometric mean using nSolver
Analysis Software v2.0 (NanoString). Biological
normalization was performed using reference genes
(CLTC, GAPDH, GUSB, HPRT1, PGK1, and TUBB)
included in the codeset. Statistical analysis of was
performed using GraphPad Prism 5 software.
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Table 1 Case demographics of cases used in the study
Cases Disease group Age at onset Age at death Disease duration Gender Post-mortem
delay (hours)
1 FTLD-FUS 41 43 2 F 55
2 FTLD-FUS 44 46 2 M 96
3 FTLD-FUS 63 59 6 F 2
4 FTLD-FUS 43 46 3 F 30
5 FTLD-FUS 69 72 3 F 90
6 FTLD-FUS 66 69 3 F 102
7 FTLD-FUS 49 55 6 F 3.5
8 FTLD-FUS 43 53 10 F 96
9 FTLD-FUS 55 58 3 F N/A
10 FTLD-FUS 40 51 11 M 12
11 FTLD-FUS 44 51 7 M 24
12 FTLD-FUS 47 53 6 M 5
13 FTLD-FUS 51 60 9 M 48
FTLD-FUS summary 50 (9.5) 55 (8.5) 5.5 (3) 5 M:8F 47 (40)
14 FTLD-TDP A 66 74 8 F 86
15 FTLD-TDP A 43 45 2 M 26
16 FTLD-TDP A 53 63 10 M 77
17 FTLD-TDP A 62 68 6 M 99
18 FTLD-TDP A 58 67 9 F 115
19 FTLD-TDP A 56 67 11 F 85.5
20 FTLD-TDP A 57 62 5 F 63
21 FTLD-TDP A 66 71 5 M 52
22 FTLD-TDP A 58 66 8 F 107
23 FTLD-TDP A 47 53 6 M 34
24 FTLD-TDP A 53 61 8 M 72.5
25 FTLD-TDP A 57 62 5 M 93
26 FTLD-TDP A 62 72 10 M 97.5
27 FTLD-TDP A 49 55 6 M 29
28 FTLD-TDP A 75 78 3 F 36
29 FTLD-TDP A 83 87 4 F 69
30 FTLD-TDP A 57 63 6 F 85
31 FTLD-TDP A 72 79 7 F 50
32 FTLD-TDP A 62 68 6 F 100
FTLD-TDP A summary 59 (10) 66 (10) 6.6 (2.4) 9 M:10F 71 (28)
33 FTLD-TDP B 67 69 2 M 70
34 FTLD-TDP B 63 67 4 F 45.5
35 FTLD-TDP B 63 83 20 F 45
FTLD-TDP B summary 64.3 (2.3) 73 (8.7) 8.6 (9.8) 1 M:2F 53.5 (14)
36 FTLD-TDP C 58 73 15 F 38
37 FTLD-TDP C 59 73 14 F 84
38 FTLD-TDP C 64 78 14 M 27
39 FTLD-TDP C 64 74 10 M 19
40 FTLD-TDP C 50 65 15 M 52
41 FTLD-TDP C 61 66 5 M 71
42 FTLD-TDP C 44 67 23 M 76
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Immunohistochemistry
Seven-micron-thick paraffin-embedded frontal cortex
and hippocampal sections were cut from the cases listed
in Table 1. Sections were deparaffinised in xylene and
rehydrated using graded alcohols. Endogenous peroxid-
ase activity was blocked with 0.3% H202 in methanol
followed by pressure cooker pre-treatment in 0.1 M cit-
rate buffer, pH 6.0. Non-specific binding was blocked
with 10% dried milk solution. Tissue sections were incu-
bated in the relevant primary antibody for 1 h at room
temperature, or overnight at 4 °C. The following primary
antibodies were used: FUS (Novus, aa1–50, 1:200),
TRN1 (Abcam, ab1303, 1:500), hnRNP R (Abcam,
ab30930 1:200), hnRNP Q (Thermo PA5–15009). Tissue
sections were incubated with the relevant biotinylated
secondary antibody (DAKO, swine anti-rabbit, 1:200, or
goat anti-mouse, 1:200) at room temperature for 30 min,
prior to incubation with avidin-biotin complex (ABC;
DAKO) for 30 min. Antibody binding was visualised by
3,3 di-aminobenzidine, activated by H2O2, and cell nu-
clei were counterstained with Mayers haemotoxylin.
Double-label immunofluorescence
Seven-micron-thick paraffin-embedded frontal cortex and
hippocampal sections were sequentially co-stained using
rabbit anti-FUS (Novus Biologicals NB100–565, 1:200)
and goat anti-hnRNP R (Santa Cruz sc-16,541, 1:200) pri-
mary antibodies. After appropriate pre-treatment, tissue
sections were incubated with the FUS primary antibody
overnight at 4 °C, followed by incubation with a swine
anti-rabbit secondary (Dako,1:200) for 1 h at room
temperature, prior to a 30min incubation with ABC. FUS
binding was visualized using TSA fluorescein amplifica-
tion kit (Perkin-Elmer). Tissue sections were then incu-
bated with goat anti-hnRNP R primary antibody overnight
at 4 °C, followed by incubation with a mouse anti-goat
secondary antibody for 1 h at room temperature, prior to
a 30min incubation with ABC. Binding of the second
antibody was visualized using TSA Cyanine 3 amplifica-
tion kit (Perkin-Elmer). Cross reactivity of antibodies was
controlled for by omitting the primary antibodies from
sections that were subsequently incubated with secondary
antibodies and TSA. Tissue sections were washed and
mounted using Vectashield anti-fade mounting medium
containing DAPI (Vector Laboratories) for nuclear coun-
terstaining. Fluorescent images were captured using a
Leica DM5500B fluorescence microscope followed by
blind 3D deconvolution.
Inclusion quantification
FUS, TRN1, hnRNP R and hnRNP Q stained slides were
scanned using a Leica Slide Scanner SCN400. Regions of
interest were digitally marked and ten random fields of
view representing a total area of 500 μm2 were generated
for each case in the frontal cortex and the granule cell
layer of the dentate gyrus using ImageJ and a Python
script. The number of FUS, TRN1, hnRNP R and hnRNP
Q positive inclusions in each field of view were manually
quantified. Statistical differences between groups was
performed using the Kruskal-Wallis one-way analysis of
variance on GraphPad Prism 5 software.
Biochemical fractionation and immunoblot analysis
Proteins were sequentially extracted using ultracentrifu-
gation in buffers of increasing stringency, adapted from
a protocol previously described [27]. To prevent carry
over, each extraction step was performed twice. Only su-
pernatants from the first extraction steps were analysed
while supernatants from the wash steps were discarded.
Tissue samples from frontal cortex (grey matter) were
homogenized at a ratio of 1:2 (weight/volume) in
high-salt buffer (50 mM Tris-HCl, 750 mM NaCl, 10
mM NaF, 5 mM EDTA) containing 1% Triton-X and
protease and phosphatase inhibitors (Roche). Tissue ho-
mogenates were initially centrifuged at 1000 g to remove
nuclear and membrane debris. The resulting supernatant
was subjected to ultracentrifugation at 120000 g for 30
min at 4 °C. The supernatant was retained and termed
the high-salt fraction. The pellet was resuspended in
radioimmunoprecipitation (RIPA) buffer (50 mM Tris–
HCl, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate) con-
taining 2% sodium dodecyl sulphate (SDS) and protease
Table 1 Case demographics of cases used in the study (Continued)
Cases Disease group Age at onset Age at death Disease duration Gender Post-mortem
delay (hours)
FTLD-TDP C summary 57.1 (7.5) 70.8 (4.9) 13.7 (5.5) 5 M:2F 52 (25)
43 Control 80 N/A N/A M 16
44 Control 79 N/A N/A F 89
45 Control 80 N/A N/A F 49
46 Control 93 N/A N/A F 30
47 Control 73 N/A N/A F 24
48 Control 83 N/A N/A F 20
Control summary 81.3 (6.6) N/A N/A 1 M:5F 14 (3.5)
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and phosphatase inhibitors. This was then subjected to
ultracentrifugation at 120000 g for 30 min at 15 °C, with
the resulting supernatant termed the RIPA-SDS fraction.
The final pellet was resuspended in 8M urea containing
8% SDS to become the urea-soluble fraction.
Protein concentrations from each fraction were de-
termined by the bicinchoninic acid protein assay
(Pierce) and 20, 20 and 5 μg of protein from the
high-salt fraction, RIPA-SDS fraction and urea frac-
tions, respectively, from each case were loaded onto
4–12% Bis–Tris polyacrylamide gels (Invitrogen) and
run at 200 V with MES [2-(N-morpholino) ethanesul-
phonic acid] buffer (Invitrogen) under reducing condi-
tions. Following electrophoresis, the proteins were
transferred onto Hybond P membrane (GE Health-
care), blocked with 5% non-fat dried milk in
phosphate-buffered saline containing 0.1% Tween and
probed overnight with primary antibody diluted in
2.5% bovine serum albumin (Sigma) in phosphate-
buffered saline containing 0.1% Tween. Following
washes in phosphate-buffered saline-Tween, blots
were developed using horseradish peroxidase conju-
gated anti-rabbit or anti-mouse IgG secondary anti-
bodies (DAKO) and visualized by an enhanced
chemiluminescence reaction (Millipore) and the
Li-Cor Odyssey imaging system (Li-Cor). The primary
antibodies used for immunoblotting were; FUS
(Novus aa1–50, 1:4000), hnRNP R (Abcam ab30930,
1:200), hnRNP Q (Millipore 05–1517, 1:500).
Results
hnRNP R mRNA expression is increased in some FTLD
subtypes
The mRNA expression of hnRNP R was analysed in the
frontal and temporal cortices of FTLD-FUS and
FTLD-TDP (Type-A, Type-B and Type-C) cases and
compared to expression in the frontal and temporal cor-
tices of neurologically normal control cases with no
pathological abnormalities. mRNA expression was ana-
lysed using NanoString technology for high-sensitive
capture of mRNA transcripts. Normalised expression in-
dicated that hnRNP R mRNA expression was significantly
increased compared to normal controls in FTLD-TDP
type A (p = 0.0005), FTLD-TDP type C (p = 0.0038) and
FTLD-FUS (p = 0.0048) subtypes relative to controls. No
significant difference in hnRNP R expression was found
between controls and FTLD-TDP type B (p = 0.5739) sub-
type (Fig. 1).
hnRNP R and hnRNP Q are localised to the nucleus in
frontal and hippocampal neurons
Given that hnRNP R expression was increased in sev-
eral FTLD subtypes, the cellular distribution of
hnRNP R, and the closely related protein, hnRNP Q
(Additional file 1: Figure S1), were investigated using
immunohistochemical staining in the frontal cortex
and hippocampus from FTLD (TDP-A, TDP-B,
TDP-C and FUS) cases. Strong neuronal nuclear
staining of hnRNP R and hnRNP Q was observed in
Fig. 1 hnRNP R expression is increased in some FTLD subtypes. Nanostring expression analysis of hnRNP R mRNA levels in the frontal and
temporal cortices of FTLD-TDP and FTLD-FUS cases compared to neurologically normal controls. A significant increase in expression of hnRNP R
was identified in FTLD-TDP A (p = 0.0005, n = 19), FTLD-TDP C (p = 0.0036, n = 7) and FTLD-FUS (p = 0.0048, n = 5) compared to controls (n = 6). No
significant difference was found between controls and FTLD-TDP B (p = 0.5739, n = 3). One-way analysis of variance
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control and all FTLD subtypes, with occasional neu-
rons additionally showing a weaker cytoplasmic stain-
ing pattern. For both proteins, the intensity of the
neuronal staining varied among cases and was
thought to be due to variation in fixation time; the
shorter the fixation time, the higher the intensity of
the staining. No pathological inclusions containing
hnRNP R or Q were detected in control cases or the
FTLD-TDP subtypes (Fig. 2).
hnRNP R and hnRNP Q are insoluble in FTLD-FUS
To establish the biochemical characteristics of both
hnRNP R and hnRNP Q in FTLD-FUS and normal
control brains, protein was sequentially extracted from
flash frozen frontal cortex. Buffers containing increas-
ing detergent strength were used to investigate the
biochemical fractions with different solubility charac-
teristics. We demonstrated that the two antibodies
recognised different proteins on the blots. Although
both hnRNP R and hnRNP Q were found in both the
soluble and detergent soluble fraction in both
FTLD-FUS and the normal controls, urea-soluble
hnRNP R and hnRNP Q was only present in
FTLD-FUS (Fig. 3).
hnRNP R and hnRNP Q form inclusions specifically in
FTLD-FUS
Post-mortem brain tissue was available from six NIFID
and seven aFTLD-U cases. These were immunohisto-
chemically assessed for hnRNP R and hnRNP Q path-
ology. All FTLD-FUS cases investigated had abundant
hnRNP R and Q immunoreactive neuronal cytoplasmic
inclusions, and occasional neuronal intranuclear inclu-
sions, in the frontal cortex and hippocampal granule cell
layer (Fig. 4). In some, but not all, neurons in the
FTLD-FUS cases, the presence of hnRNP R or Q immu-
noreactive inclusions depleted the normal nuclear stain-
ing of these proteins. However, this was variable
between cases, and may reflect variation in tissue fix-
ation time.
Between each case, the abundance and distribution of
inclusions stained with hnRNP R or hnRNP Q varied
but within each case the staining was comparable to
FUS and TRN1 immunohistochemistry, which has previ-
ously been reported for these cases [6, 27]. As with FUS
and TRN1 staining, the NIFID cases consistently showed
more hnRNP R and hnRNP Q positive inclusions than
aFTLD-U cases. In the hippocampus, hnRNP R and
hnRNP Q immuno-reactive neuronal cytoplasmic inclu-
sions were observed in dentate gyrus granule cell layer
Fig. 2 hnRNP R and hnRNP Q localise to the nucleus in the frontal cortex and hippocampus in FTLD-TDP and normal controls. Representative images
of hnRNP R and hnRNP Q immunohistochemistry in the frontal cortex and granular cell layer of the dentate gyrus in a neurologically normal control
and the FTLD-TDP subtypes (TDP-A, TDP-B, TDP-C and FUS). Strong neuronal nuclear hnRNP R and hnRNP Q staining is observed in both controls and
the FTLD-TDP subtypes, with occasional weak cytoplasmic staining in some neurons. Scale bar represents 50 μm in all images
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in both NIFID and aFTLD-U subtypes, although the
frequency of inclusions was much higher in the NIFID
subtype (Fig. 4). These inclusions were typically
bean-shaped or Pick-like structures adjacent to the nu-
cleus, however occasional crescent-shaped inclusions
surrounding nuclei were also observed. In some cases,
hnRNP R and hnRNP Q neuronal vermiform inclusions
were also observed in the granular cell layer in both
NIFID and aFTLD-U subtypes. Additionally,
crescent-shaped neuronal cytoplasmic inclusions and
rod-like structures in neuronal intranuclear inclusions
were observed (Fig. 5) as previously described for FUS
and TRN1 staining in these cases.
In the frontal cortex, crescent-shaped neuronal cyto-
plasmic inclusions surrounding the nucleus containing
hnRNP R and Q were frequently observed in both
NIFID and aFTLD-U cases (Fig. 5a and b), as well as
dense, bean-shaped or larger Pick-body-like structures
adjacent to the nucleus (Fig. 5c and d). Neuronal intra-
nuclear inclusions were also observed in both
FTLD-FUS subtypes, but at a much less frequent rate
than neuronal cytoplasmic inclusions. These typically
formed a rod-like structure through the nucleus (Fig. 5g
and h). Similar to FUS and TRN1 staining, hnRNP R
and Q immunoreactive neuronal cytoplasmic and intra-
nuclear inclusions were less frequently observed in the
cortex of aFTLD-U cases than NIFID cases. hnRNP R
and Q immunoreactive dystrophic neurites were also ob-
served through the cortex of both NIFID and aFTLD-U
cases (Fig. 5e and f).
hnRNP R and hnRNP Q are detected in inclusions as
frequently as FUS and TRN1
To quantitatively assess the abundance of pathological
inclusions containing hnRNP R and hnRNP Q relative
Fig. 3 hnRNP R and Q are insoluble in FTLD-FUS. Representative immunoblots demonstrating hnRNP R and hnRNP Q in fractions of varying
solubility in FTLD-FUS and normal control brains. Proteins were sequentially extracted into high salt (lane 1), RIPA/ 2% SDS (lane 2), and 8 M urea
/ 8% SDS (lane 3) fractions. 20 μg of protein was loaded from high salt and RIPA-SDS fractions, while 5 μg of protein was loaded from the urea
fractions. Two prominent bands were observed for hnRNP R, whilst a single band was observed for hnRNP Q. Only the FTLD-FUS cases showed
bands in the insoluble urea fraction for both proteins
Fig. 4 hnRNP R and hnRNP Q form frequent inclusions in FTLD-FUS.
Representative images of FUS, TRN1, hnRNP R and hnRNP Q
immunohistochemical staining in the granule cell layer of the
dentate fascia of the hippocampus in NIFID and aFTLD-U subtypes
of FTLD-FUS. Single arrows indicate neuronal cytoplasmic inclusions
and double arrows highlight intranuclear inclusions. Scale bars
represent 50 μm in all images
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to FUS or TRN1 in FTLD-FUS cases, the number of
FUS, TRN1, hnRNP R and hnRNP Q positive inclusions
on immunohistochemically stained sections were
counted in a defined area of the grey matter of the
frontal cortex (Fig. 6a) and in the granule cell layer of
the dentate gyrus in the hippocampus (Fig. 6b). Inclusion
quantification indicated variation between cases in the
number of all inclusions counted, however no statistically
significant differences were found between the average
number of FUS, TRN1, hnRNP R and hnRNP Q positive
inclusions in both NIFID (frontal cortex p = 0.7978, den-
tate gyrus p = 0.9723) and atypical FTLD-FUS (frontal cor-
tex p = 0.2856, dentate gyrus p = 0.8934) subtypes. As
expected, the number of FUS, TRN1, hnRNP R and
hnRNP Q positive inclusions were consistently higher in
the NIFID cases than aFTLD-U.
hnRNP R and FUS co-localise in inclusions in FTLD-FUS
To investigate whether the pathological inclusions la-
belled with hnRNP R also contained FUS, double im-
munofluorescence staining was performed on both
NIFID and aFTLD-U cases (Fig. 7). Due to the anti-FUS
antibody and anti-hnRNP Q antibody being raised in the
same species, double immunofluorescence staining with
these two antibodies was unable to be performed. Quali-
tative assessment of the fluorescence images indicated
that, in all FTLD-FUS cases assessed, hnRNP R
co-localised with FUS in neuronal cytoplasmic and intra-
nuclear inclusions in the cerebral cortex and granule cell
layer of the dentate gyrus in the hippocampus, in both
NIFID (Fig. 7a and c) and aFTLD-U (Fig. 7b and d) cases.
Discussion
This study has shown for the first time that hnRNP R
and hnRNP Q are mislocalised into pathological inclu-
sions in two subtypes of FTLD-FUS, expanding the
spectrum of DNA/RNA binding proteins linked to FTLD
pathobiology. mRNA expression analysis revealed that
hnRNP R expression was increased in FTLD-TDP A,
FTLD-TDP B and FTLD-FUS subtypes but immunohis-
tochemical examination demonstrated that this protein,
and the closely related hnRNP Q protein, only show
pathological mislocalisation specifically in FTLD-FUS.
We have previously shown an increase in mRNA expres-
sion of other hnRNP proteins in FTLD-FUS, however
Fig. 5 hnRNP R (a, c, e and g) and hnRNP Q (b, d, f and h) form a
range of inclusions types in FTLD-FUS. Immunohistochemical
staining demonstrates the different pathological inclusions types
found to be immunoreactive with anti-hnRNP R and anti-hnRNP Q
antibodies. Crescent neuronal cytoplasmic inclusions (a and b),
bean-shaped neuronal cytoplasmic inclusions (c and d), dystrophic
neurites (e and f) and intranuclear neuronal inclusions (g and h).
Scale bars represent 10 μm in all images
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these proteins were not identified in the pathological in-
clusions [17]. The pathological inclusions containing
hnRNP R and hnRNP Q in the frontal cortex and
hippocampus of these cases had a similar localisation
pattern and morphological features to the previously
described FUS and TRN1 inclusions [6, 27]. Quantifi-
cation of hnRNP R and hnRNP Q inclusions indi-
cated they were as frequent as inclusions containing
FUS or TRN1, and double-immunofluorescence con-
firmed the co-localisation of hnRNP R with FUS in
both neuronal cytoplasmic and intranuclear inclu-
sions. Additionally, biochemical fractionation demon-
strated a shift in the solubility of hnRNP R and
hnRNP Q in a similar manner as we previously re-
ported for FUS and TRN1 in the FTLD-FUS cases
[6]. These findings reinforce the hypothesis that the
pathogenesis of FTLD-FUS extends beyond the FET
proteins, known TRN1 cargoes and dysfunctional
nuclear import, but rather implicates a broader dys-
regulation of DNA/RNA binding proteins.
hnRNP R and hnRNP Q are multi-functional,
RNA-binding proteins containing three RNA recogni-
tion motifs, one acidic rich domain and an RGG do-
main [21, 38]. Despite being widely expressed in
neuronal tissue little is known about these hnRNP in
the context of neurodegenerative diseases [44]. The
two proteins have high sequence homology with se-
quence alignment of their canonical isoforms showing
that they are 81.2% identical at the amino acid level
[37]. Consequently, they are known to have similar, but
distinct, functional roles within the cell [8, 19, 37].
hnRNP R is involved in axonal RNA transport and
processing, the expression of immunity factors, and
transcription and degradation process of c-fos mRNA
[11, 16, 23, 49], whilst hnRNP Q, also known as SYN-
CRIP, is implicated in the maintenance of circadian
Fig. 6 hnRNP R and hnRNP Q inclusions occur as frequently as FUS and TRN1 inclusions. Quantification of FUS, TRN1, hnRNP R and hnRNP Q
inclusions in the frontal cortex (a) and granular cell layer of the hippocampus (b) in NIFID and aFTLD-U cases. No significant differences were
found between the number of each inclusion type in either FTLD-FUS subtype in either brain region. Kruscall-Wallis one-way analysis of variance.
a NIFID cases, n = 5, p = 0.7978. aFTLD-U cases, n = 5, p = 0.2856. b NIFID cases, n = 6, p = 0.9723. aFTLD-U cases, n = 5, p = 0.8934
Fig. 7 hnRNP R co-localises with FUS inclusions in NIFID and aFTLD-U cases. Representative images of double-label immunofluorescence in the
cortex (a and b) and granular cell layer of the dentate gyrus (c and d) of a NIFID and aFTLD-U case demonstrating colocalisation of FUS (green)
and hnRNP R (red) in neuronal cytoplasmic inclusions (white arrows) and intranuclear neuronal inclusions (white arrow heads). Neuronal nuclei
are counterstained with DAPI. Scale bars represent 20 μm in all images
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rhythms and be involved in the regulation of mRNAs
responsible for neuronal morphogenesis [10, 25, 31].
Both proteins are known to interact with the survival
motor neuron (SMN) protein [1] and be involved in
pre-mRNA splicing as components of the spliceosome
[9, 38, 51, 56]. Recent analysis of these proteins in a cellu-
lar model has found them to be important regulators of
neuronal homeostasis and indicated that their disruption
could impair distinct pathways in the central nervous sys-
tem axis [8]. Interestingly, a link between TDP-43 and
hnRNP Q has previously been reported as hnRNP Q is
capable of rescuing TDP-43 toxicity in Drosophila mela-
nogaster model [3], whilst significant alterations in hnRNP
Q were found in ALS compared controls [4]. In contrast,
no interactions have previously been reported between
FUS and hnRNP R or hnRNP Q.
A prominent hypothesis to explain the pathogenesis of
FTLD-FUS is that pathological aggregation of FUS and
other FET proteins results from an impaired interaction
with their nuclear importer, TRN1 [34, 43]. It is believed
that this may be a result of impaired methylation of ar-
ginine residues in the RGG3 domains of the FET pro-
teins, which causes overly tight binding of the FET
proteins to TRN1. A consequence of this aberrant bind-
ing is lack of dissociation of the FET-TRN1 complex
once inside the nucleus, resulting in the re-export of the
complex and accumulation of FET proteins and TRN1
in the cytoplasm [12, 13]. Recent work has also shown
that aberrant arginine methylation of FUS, as seen in
FTLD-FUS patients, promotes the phase transition of
FUS into liquid-like droplets which form solid, fibrous
aggregates over time, promoting their pathological ag-
gregation [22, 47]. Given the structural and functional
similarity between the FET proteins, it is possible that
arginine methylation may have a similar effect on EWS
and TAF15, although this remains to be investigated.
Whilst this hypothesis can explain the presence of TRN1
and the three FET proteins in pathological inclusions in
FTLD-FUS, it cannot explain the pathological accumula-
tion of non-FET proteins, such as hnRNP R, hnRNP Q
and the other hnRNP proteins previously identified in
these inclusions [17]. With the exception of hnRNP A1
and hnRNP D, the majority of these proteins are not
predicted to be imported by TRN1 [30, 45, 53], and it is
unclear to what extent these proteins are capable of
liquid-liquid phase separation or subject to the effects of
arginine methylation. This suggests that it is not only
the FET proteins that are responsible for FTLD-FUS
pathology but rather implicates dysfunction in a broader
spectrum of RNA binding proteins. Unlike EWS, TAF15
and other hnRNPs, which are only found in a proportion
of FUS inclusions, quantification of hnRNP R and
hnRNP Q inclusions revealed that these proteins are
found as frequently as FUS and TRN1 in inclusions.
This suggests these proteins have a central role in the
pathogenesis of FTLD-FUS, however it is currently un-
clear, whether the accumulation of these proteins is a
trigger or consequence of FUS aggregation.
FUS, hnRNP R and hnRNP Q are all RNA binding pro-
teins that have a wide range of functions linked to various
aspects of mRNA metabolism. They have all been re-
ported to bind to the SMN protein spliceosome complex
and are all known to shuttle between the nucleus and
cytoplasm associated with mRNAs [38, 51, 57]. This indi-
cates these proteins have similar functions and could sug-
gest that they interact with each other under physiological
conditions within the cell. One hypothesis to explain the
co-aggregation of FUS, hnRNP R and hnRNP Q could be
that these proteins associate with each other in a
protein-RNA complex, either directly via a protein-protein
interaction, or indirectly by binding to the same mRNA
transcripts. If the proteins form part of the same complex,
then aberrant aggregation of one of the proteins could
trigger the co-deposition of the associated proteins. It may
also be possible that FUS and hnRNP R and hnRNP Q do
not interact with each other physiologically and localise to
pathological aggregates independently. Endogenous FUS
and hnRNP Q have both been shown to localise to cyto-
plasmic stress granules under specific cellular stress con-
ditions [48, 52]. It may therefore be possible that these
proteins co-localise in stress granules only during cellular
stress and it is the aberrant disassembly of these granules
that results in co-aggregation of these proteins in patho-
logical inclusions. Several groups have proposed that the
pathological accumulation of FUS, and other ALS/
FTD linked proteins, is initiated by their assembly in
stress granules or other RNA granules [5, 14, 32].
The mechanism by which FUS condenses into stress gran-
ules by liquid-liquid phase separation is well-characterised
and is known to be driven by cation-pi interactions be-
tween tyrosine in its N-terminal LCD domain and argin-
ine residues in the C-terminal RGG domain [22, 47].
Whether hnRNP R and hnRNP Q possess similar phase
transitioning properties that enable them to condense into
stress granules is currently unknown and requires further
investigation. Both hnRNP proteins contain C-terminal
RGG domains but only hnRNP R is predicted to have a
LCD domain.
The identification of hnRNP R and/or hnRNP Q in
pathological inclusions in FTLD-FUS provide two candi-
date genes for genetic screening in FTLD. All
FTLD-FUS cases used in this study have previously been
screened for mutations in a variety of genes linked to
FTD and ALS [27, 50], but to date, no genetic mutations
have been identified as causative of FTLD-FUS. Screen-
ing the HNRNPR and HNRNPQ genes for mutations in
these cases could identify mutations linked to disease. It
would also be interesting to screen for mutations and
Gittings et al. Acta Neuropathologica Communications            (2019) 7:18 Page 10 of 13
assess hnRNP R and hnRNP Q pathology in ALS-FUS
cases. To date, none of the additional proteins identified
in FTLD-FUS inclusions have been found in ALS-FUS
inclusions [43]. This is hypothesised to reflect the differ-
ing pathogenic mechanisms of the diseases, however, the
end-point in both diseases is the pathological aggrega-
tion of FUS and it is possible that other proteins associ-
ated with FUS will also be common to both diseases.
ALS-FUS cases should therefore be assessed for hnRNP
R and hnRNP Q pathology to determine whether the
dysregulation of these proteins is specific to FTLD-FUS
or is a common feature shared by FUS pathologies.
In summary, the identification of hnRNP R and
hnRNP Q in pathological inclusions in the FTLD-FUS
cases adds two new proteins to the growing list of RNA
binding proteins implicated in the pathogenesis of
FTLD. Disease causing mutations in TDP-43, FUS,
hnRNP A1, hnRNP A2B1, MATR3 and TIA1 all point to
disturbed function of RNA binding proteins, especially
hnRNPs, as playing a role in the pathogenesis of FTD
and ALS [46]. The accumulation of these proteins in
cytoplasmic and intranuclear neuronal inclusions was
found to be specific to FTLD-FUS cases, although in-
creased hnRNP R mRNA expression was also seen in
several FTLD-TDP subtypes. These inclusions were
found to co-localise with and occur as frequently as in-
clusions containing FUS, suggesting these proteins may
play a role in the pathogenesis of FTLD-FUS. The rela-
tionship between FUS and these hnRNP proteins has
not been previously explored and future experiments
should be performed to establish whether these proteins
directly or indirectly associate with FUS as this may help
to establish the mechanism by which these proteins
co-aggregate. Future biochemical experiments are also re-
quired to address whether it is both hnRNP R and hnRNP
Q accumulating in these inclusions because the high level
of homology between these proteins has made this diffi-
cult to decipher by immunohistochemical methods. Fur-
ther functional understanding of these two new RNA
binding proteins in FTLD-FUS aggregates may help to
elucidate the mechanism by which these inclusions form
and reveal novel functions for these hnRNP proteins.
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